Affordable Access

Role of the histone deacetylase complex in acute promyelocytic leukaemia.

Authors
  • Lin, R J
  • Nagy, L
  • Inoue, S
  • Shao, W
  • Miller, W H Jr
  • Evans, R M
Type
Published Article
Journal
Nature
Publication Date
Feb 19, 1998
Volume
391
Issue
6669
Pages
811–814
Identifiers
PMID: 9486654
Source
Medline
License
Unknown

Abstract

Non-liganded retinoic acid receptors (RARs) repress transcription of target genes by recruiting the histone deacetylase complex through a class of silencing mediators termed SMRT or N-CoR. Mutant forms of RARalpha, created by chromosomal translocations with either the PML (for promyelocytic leukaemia) or the PLZF (for promyelocytic leukaemia zinc finger) locus, are oncogenic and result in human acute promyelocytic leukaemia (APL). PML-RARalpha APL patients achieve complete remission following treatments with pharmacological doses of retinoic acids (RA); in contrast, PLZF-RARalpha patients respond very poorly, if at all. Here we report that the association of these two chimaeric receptors with the histone deacetylase (HDAC) complex helps to determine both the development of APL and the ability of patients to respond to retinoids. Consistent with these observations, inhibitors of histone deacetylase dramatically potentiate retinoid-induced differentiation of RA-sensitive, and restore retinoid responses of RA-resistant, APL cell lines. Our findings suggest that oncogenic RARs mediate leukaemogenesis through aberrant chromatin acetylation, and that pharmacological manipulation of nuclear receptor co-factors may be a useful approach in the treatment of human disease.

Report this publication

Statistics

Seen <100 times